|
|
Volumn 102, Issue 2, 2010, Pages
|
|
Should cetuximab replace cisplatin in head and neck cancer?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
CISPLATIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
MONOCLONAL ANTIBODY;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
ALPHAPAPILLOMAVIRUS;
CLINICAL TRIAL;
DRUG ANTAGONISM;
EUROPE;
HEAD AND NECK TUMOR;
HUMAN;
META ANALYSIS;
NOTE;
PAPILLOMAVIRUS INFECTION;
TREATMENT OUTCOME;
UNITED STATES;
VIROLOGY;
VIRUS INFECTION;
ALPHAPAPILLOMAVIRUS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, ADJUVANT;
CISPLATIN;
CLINICAL TRIALS AS TOPIC;
EUROPE;
HEAD AND NECK NEOPLASMS;
HUMANS;
META-ANALYSIS AS TOPIC;
PAPILLOMAVIRUS INFECTIONS;
RADIOTHERAPY, ADJUVANT;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TREATMENT OUTCOME;
TUMOR VIRUS INFECTIONS;
UNITED STATES;
|
|
EID: 75649110453
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp531 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
